Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT known ✓ | P43490 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30935911 | 0.95 | KDM1A (0.58) | KDM1AEGFRMAPTGAAALDH1A1 | |
| SCHEMBL3196135 | 0.95 | KDM1A (0.58) | KDM1AEGFRMAPTGAAALDH1A1 | |
| SCHEMBL14127728 | 0.82 | KDM1A (0.56) | KDM1AEGFRMAPTGAAALDH1A1 | |
| SCHEMBL29624619 | 0.82 | KDM1A (0.56) | KDM1AEGFRMAPTGAAALDH1A1 | |
| SCHEMBL5885190 | 0.82 | KDM1A (0.61) | KDM1AEGFRMAPTGAAALDH1A1 | |
| SCHEMBL24914503 | 0.80 | KDM1A (0.58) | KDM1AMAPTGAAALDH1A1TP53 | |
| SCHEMBL25734260 | 0.80 | KDM1A (0.46) | KDM1AEGFRMAPTGAAALDH1A1 | |
| SCHEMBL6568199 | 0.78 | KDM1A (0.47) | KDM1AEGFRMAPTGAAALDH1A1 | |
| SCHEMBL31718394 | 0.78 | KDM1A (0.47) | KDM1AEGFRMAPTGAAALDH1A1 | |
| SCHEMBL24914440 | 0.77 | KDM1A (0.56) | KDM1AEGFRMAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793504-B2 | Methods for cross coupling | RECURIUM IP HOLDINGS, LLC (US) | 2020-10-06 | — | — | US | claimed |
| US-20190202769-A1 | METHODS FOR CROSS COUPLING | RECURIUM IP HOLDINGS, LLC | 2019-07-04 | — | — | US | claimed |
| EP-3504217-A1 | METHODS FOR CROSS COUPLING | Zeno Royalties & Milestones, LLC (US) | 2019-07-03 | — | — | EP | claimed |
| WO-2018039232-A1 | METHODS FOR CROSS COUPLING | KALYRA PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | WO | claimed |
| US-10793504-B2 | Methods for cross coupling | RECURIUM IP HOLDINGS, LLC (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190202769-A1 | METHODS FOR CROSS COUPLING | RECURIUM IP HOLDINGS, LLC | 2019-07-04 | — | — | US | disclosed |
| EP-3504217-A1 | METHODS FOR CROSS COUPLING | Zeno Royalties & Milestones, LLC (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018039232-A1 | METHODS FOR CROSS COUPLING | KALYRA PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2013041106-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS 11CO FOR CARBONYLATION REACTIONS IN THE PREPARATION OF RADIOPHARMACEUTICALS FOR PET IMAGING | AARHUS UNIVERSITET (DK) | 2013-03-28 | — | — | WO | disclosed |
| WO-2012079583-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS CO FOR CARBONYLATION REACTIONS | AARHUS UNIVERSITET (DK) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202769-A1 | METHODS FOR CROSS COUPLING | F2, C5, C9 | NAMPT 2907/4885KDM1A 1208/4885EGFR 3170/4885 |
| US-10793504-B2 | Methods for cross coupling | F2, C5, C9 | NAMPT 2907/4885KDM1A 1208/4885EGFR 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.